
Kit Gallagher
@scikit_g
PhD student at Uni of Oxford and Moffitt Cancer Center
Using deep learning and modelling to improve treatment schedules and patient outcomes in prostate cancer
ID: 1653533779493806081
02-05-2023 22:55:59
54 Tweet
226 Followers
162 Following

Exciting work by Maximilian Strobl at #SMB2024 combining math models and in vitro trials to systematically compare treatment schedules for EGFR+ NSCLC. Could this herald a new framework for bringing new schedules into clinic, akin to traditional drug development pipelines? #mathonco



This week in #MathOnco is back! Cell-state transitions, adaptive therapy, spatio-temporal dynamics, and more... Art: Kit Gallagher (Kit Gallagher) 😎💯


I think this is a really cool study: evolution and heterogeneity predict long-term outcomes in prostate cancer. Worth emphasising that the lab team were blinded to clinical outcomes until a final great reveal: no risk of over-fitting here! Congrats Andrea Sottoriva and team


This remarkable study essentially validated our earlier finding in ALK+ NSCLC with @RobertVanderVe1 and Jake Scott that resistance is acquired through a trajectory rather than a switch nature.com/articles/s4146….


Interested in the evolution of drug resistance? Or working with animal models & clinical data to implement new a Centre for Evolutionary Therapy for NSCLC? The #AndersonLab is hiring a postdoc to work in IMO on our @NCIsysbio U54: The Delta Ecology of NSCLC. More here: labpages.moffitt.org/andersona/jobs…


This week in #MathOnco 303: Spatial landscapes, tumor organoids, neural-ODE's, drug tolerance, and more... Art: Maximilian Strobl (Maximilian Strobl), Kit Gallagher (Kit Gallagher), Jeffrey West (Jeffrey West), Jill Gallaher (Jill Gallaher), Mark Robertson-Tessi (Mark R-T), Sandy Anderson



Interested in teaching or code quality? How does good code quality improve research outcomes, and how can we instil this in new graduate students? We share lessons from Oxford DTC teaching sustainable software development to science PhDs in PLOS Comp Biol doi.org/10.1371/journa…


The AirMed landing while we chatted about modelling competition assays summed up my visit to Cleveland Clinic , and their exciting work integrating game theory and evolutionary steering into clinical practice. Thanks for many illuminating discussions Jake Scott Maximilian Strobl


With just over 2 weeks until the 12th IMO Workshop I'm excited to share the artwork for the Toxicity focus! As always the brilliant Jill Gallaher drove this grunge influenced innovation with help from Chandler Gatenbee. Can you spot the other influence? IMO Moffitt Cancer Center #MoffittIMO


Thanks Moffitt Cancer Center for the $50k pilot grant to develop 2nd line treatment options for HR proficient Ovarian cancer patients (~85% relapse on 1st line chemo), through biomarkers predictive of toxicity and modeling of synergistic drug scheduling & microbiome activation! #mathonco



Two wheels good. 'Make yourself useful' is one of those English phrases that frustrated parents might bark at their kids. But sometimes it is directed at mathematicians. Kit Gallagher is more than up to the task.

Why does this heterogeneity occur in adaptive therapy, and is a 'one-size-fits-all' protocol best for patients across this spectrum of responses? Join Kit Gallagher (Kit Gallagher) at #AACR25 as he shares a new mathematical biomarker that can be used to predict treatment outcomes


From #AACR25, Alexander Anderson, PhD (Sandy Anderson) and Kit Gallagher (Kit Gallagher) discuss using a mathematical biomarker to predict treatment outcomes from adaptive therapy. #MoffittAACR25


Save the date #MathOnco25! October 29th-31st in Tampa, Florida. Directly before the 13th IMO Workshop (November 3rd-7th) - stay the weekend and brainstorm the beaches! More information to follow but Centre for Evolutionary Therapy will be a key theme IMO Moffitt Cancer Center
